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1. Abstract: 
  
Fibrinolysis represents an essential mechanism for maintenance of the 
haemostatic balance. Herein, in the process regulated by a multitude of 
enzymes, the activation of inactive protease plasminogen to the active 
plasmin describes a crucial step. By resolving blood clots (thrombi), plasmin 
counteracts blood coagulation. Plasmin degrades fibrin polymers, which 
represent the main components of thrombi. In addition to clot resolving, 
plasmin is commonly used by cells, e.g. immune and endothelial cells, to 
facilitate migration. Based on its broad spectrum of activity, plasmin and its 
regulatory molecules not only play an important role in various physiological 
but also in pathological processes. In case of Alzheimer’s disease, 
plasminogen levels as well as plasmin activity in the brain are reduced, which 
could play a role in development or progression of this disease. On the other 
hand, plasmin facilitates metastasis of cancer cells by degrading extracellular 
matrix components, thereby allowing tumor cells to invade tissues, evade the 
immune system or local nutrient limitations. In the following work a novel 
regulator of the fibrinolytic system is characterized. Its binding to plasminogen 
and functional consequences are investigated by the use of molecular 
biological, biochemical and cell biological methods. Ultimately, a synthetic 
peptide derived from this regulatory protein is presented, which might provide 
a therapeutic tool.  
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2. Introduction: 
2.1. The plasminogen/plasmin system: 
Plasmin (Plm) is a serine protease with broad range specificity involved in 
many physiological processes like fibrinolysis or re-organization of the 
extracellular matrix, hence defining the integrity of our connective tissues. Plm 
is synthesized as the inactive zymogen plasminogen (Plg) in the liver (Raum 
et al., 1980), and is released into the bloodstream where it is present at a 
concentration of about 2 µmol/L. (Cederholm-Williams, 1981) Plg can be 
proteolytically converted to active Plm (Robbins et al., 1967) by a variety of 
enzymes. For instance urokinase-type plasminogen activator (urokinase, 
uPA) or tissue plasminogen activator (tPA) are able to catalyze the proteolytic 
conversion to active Plm. Both, uPa and tPA, can be inhibited by plasminogen 
activator inhibitors (PAI) 1 and 2. (Schaller and Gerber) While tPA can 
perform its action directly, uPA has to be produced by proteolytic cleavage 
from its zymogen pro- (or single-chain) urokinase (pro-uPA, sc-uPA), which 
has only little intrinsic activity. (Pannell and Gurewich, 1987) The conversion 
of pro-uPA to uPA is accomplished by Plm thereby generating a positive 
feedback loop. (Blasi et al., 1987; Petersen et al., 1988) Since uPA is bound 
to the urokinase-type plasminogen activator receptor (uPAR, PLAUR, CD87) 
which is tethered to the cell membrane via a GPI anchor, Plg conversion by 
uPA is restricted to the cell surface. Moreover, free Plm is blocked by alpha 2-
antiplasmin (α2AP) and alpha 2-macroglobulin, two protease inhibitors 
repressing its action. (Schaller and Gerber)  Consequently, Plm can only be 
active when it is bound to cells or matrix. In addition to tPA and uPA, kallikrein 
(Colman, 1969), factor XIa  and XIIa (Mandle and Kaplan, 1979) can directly 
elicit the conversion of Plg to active Plm. Upon Plg cleavage not only Plm is 
formed, but in addition the angiogenesis inhibitor called angiostatin is 
produced. (Castellino and Ploplis, 2005) Plm and its main regulators are 
illustrated in figure 1.  
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In terms of fibrinolysis, Plm resolves blood clots formed by coagulation and 
therefore is the key enzyme of this central physiological event. (Ratnoff, 1948) 
The process of coagulation is based on a multitude of zymogens circulating in 
the blood stream which get activated upon blood vessel damage. (Macfarlane, 
1964) Injured vessel walls trigger the release of several factors; the most 
prominent von Willebrand factor (vWF) binds collagen, thereby facilitating 
platelet adhesion. (Nyman, 1980) Von Willebrand factor in addition binds 
several clotting factors which trigger an amplifying cascade resulting in active 
thrombin which in turn converts fibrinogen to fibrin. Latter one forms a tight 
meshwork by polymerization, hence provoking the formation of blood clots. 
Consequently, the bleeding stops and wound healing is initiated. Plm on the 
other hand counteracts coagulation by degrading these thrombi. (Francis and 
Marder, 1982) Since hypo- as well as hyper-function of the fibrinolytic system 
might pose serious health risks, it needs to be tightly regulated.  
Furthermore, Plm can trigger extracellular matrix modulation by activating 
metalloproteases (MMPs). (Quigley et al., 1990) These findings underline the 
important role Plm plays in natural cell migration and wound healing. (Chan et 
al., 2001; Li et al., 2003) Apart from modifying the pericellular 
microenvironment, the Plm system directly regulates cellular adhesion via 
uPAR which binds to integrins (Simon et al., 2000) and intercedes with 
Fig. 1.:  Plasmin and its main regulators: 
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integrin signaling cascades. (Aguirre Ghiso et al., 1999; Wei et al., 1999) The 
Plg/Plm system with its major interaction partners is schematically depicted in 
figure 2. 
 
 
Evidences for engagement of the fibrinolytic system in several pathological 
processes evolved during the last decades. Hitch-hiking the fibrinolytic system 
is a prevalent feature amongst a number of bacteria (Kitano et al., 1981; 
Lewis et al., 1949) and viruses (Howett et al., 1978; Lazarowitz et al., 1973) 
which exploit the cellular machinery in order to invade host tissues. For 
instance, staphylococcal staphylokinase (Kowalska-Loth and Zakrzewski, 
1975) and streptococcal streptokinase (Troll and Sherry, 1955) are able to 
activate Plg, and consequently the Plm triggered remodeling of the 
extracellular matrix enables bacterial migration (Eberhard et al., 1999). 
Moreover, Plm is mediating inflammation either directly or through its 
cleavage products. For instance, fibrin degradation products are able to 
influence inflammation by regulating vascular permeability. (Sueishi et al., 
1981; Triantaphyllopoulos, 1976)  
Additionally, Plm is cleaving amyloid beta precursor protein (APP) and 
degrading amyloid beta peptide (Aβ), which is responsible for the formation of 
Alzheimer’s disease related plaques in the brain. (Ledesma et al., 2000) In 
Fig.2.: The plasminogen/plasmin system:  
A scheme of the uPAR dependent Plg activation on the cell surface 
A novel interaction partner of plasminogen in regulation of fibrinolysis       Alexander Zwirzitz  
 9 
fact, uPA and Plg levels decrease in an age-related manner, leading to 
reduced activity of brain Plm. (Aoyagi et al., 1994)  
The Plm system also plays a fundamental role in cancer. Tumor cells utilize 
the fibrinolytic system to escape spatial nutrient supply limitations and flee 
from local opponents belonging to the immune system. Notably, increased 
Plm and uPA activity favours metastasis due to exaggerated breakdown of 
extracellular matrix components, thereby enabling enhanced mobilization of 
tumor cells. (Goldberg et al., 1990; Hearing et al., 1988) In addition, cancer 
cells empower themselves to metastasize from local tissues to distinct parts of 
the body by using components of the Plm system which interact with integrins 
(Simon et al., 2000) and facilitate angiogenesis (Yasunaga et al., 1989). Since 
Plg activation requires regulation by uPA and uPAR, the whole fibrinolytic 
system seems to be involved in cancer progression and metastasis. (Dass et 
al., 2008) In fact, the expression of some of its components (e.g. uPA or 
uPAR) is modulated by growth factors and cytokines. Both are over-
expressed by tumor cells and can be used as prognostic tumor markers. 
(Hildenbrand et al., 2009; Kwaan and McMahon, 2009)  
In a nutshell, the regulation of Plg conversion to active Plm plays an important 
role in a wide variety of physiological as well as pathological processes. 
Therefore, it is absolutely necessary to investigate molecules implicated in the 
fibrinolytic system in order to get a better understanding of the human body 
and its dysfunctions.  
 
2.2. The mannose 6 phosphate / insulin like growth factor 2 receptor: 
The cation independent mannose 6-phosphate or insulin like growth factor 2 
receptor (CI-MPR, M6P/IGF2R or CD222) is a multifunctional protein, which is 
considered a tumor suppressor. (Gary-Bobo et al., 2007) The ubiquitously 
expressed 250 kDa type I transmembrane protein M6P/IGF2R binds many 
distinct and structurally, as well as functionally, different ligands and thus is 
capable of accomplishing numerous diverse tasks like protein trafficking and 
internalization. Over 90% of the total amount of receptor molecules is located 
inside the cell within cellular substructures such as vesicles, early and late 
endosomes and especially the Golgi apparatus, whereas only 5 to 10% are on 
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the cell surface. (Scott and Firth, 2004) Its major physiological role known so 
far is sorting proteins from the trans Golgi network, in particular targeting 
newly synthesized M6P-tagged enzymes to lysosomes and recycling 
membrane vesicles. (Ni et al., 2006) Indeed, M6P/IGF2R seems to be more 
efficient in endocytosis and trafficking proteins intracellularly rather than 
exporting them to the plasma membrane. (Hille-Rehfeld, 1995) Furthermore, 
M6P/IGF2R exhibits the capacity of suppressing tumor growth on the one 
hand by internalization, and thereby facilitating degradation of cellular growth 
factors, like insulin-like growth factor 2 (IGF2) (Mathieu et al., 1990), and on 
the other hand by activation of e.g. latent transforming growth factor beta 
(TGF-β) (Godar et al., 1999), therefore regulating cell proliferation and growth. 
(Leksa et al., 2005) In addition, some of M6P/IGF2Rs ligands like granzyme B 
(Motyka et al., 2000) or retinoic acid (Kang et al., 1997) were shown to induce 
apoptosis, thus generating strong evidence for the participation of M6P/IGF2R 
in the process of programmed cell death.  
According to previously published data of our group, M6P/IGF2R is 
responsible for the elevated cleavage of uPAR. Upon silencing of 
M6P/IGF2R, molecules like uPA, Plg and also αVβ3 integrins accumulate at 
the cell surface. Hence, pericellular Plg activation is increased, which results 
in augmented cellular motility. (Schiller et al., 2009) Indeed, M6P/IGF2R is 
also involved in cell migration. (Leksa et al., 2002) Moreover, M6P/IGF2R is 
considered as a tumor suppressor due to its ability to control αV integrin 
homeostasis which is closely linked to metastasis. (Felding-Habermann et al., 
2001) Another tumor suppressive feature of M6P/IGF2R is regulating the 
turnover of enzymes participating in degradation of extracellular matrix 
components. (Martin-Kleiner and Gall Troselj, 2010; Sengupta et al., 2001) 
 
2.3. Lactoferrin: 
Human lactoferrin (hLF, LF) is an 80 kDa glycoprotein abundantly present in 
secretions of all mammals and is officially denoted as lactotransferrin (LTF). It 
was also described as lactosiderophilin (Montreuil and Mullet, 1960) or red 
milk protein when discovered. (Blanc and Isliker, 1961) A recombinant form of 
LF is currently used in clinical trials with the commercial name talactoferrin. 
A novel interaction partner of plasminogen in regulation of fibrinolysis       Alexander Zwirzitz  
 11 
(Digumarti et al., 2011) LF is especially enriched in milk, tears, saliva and the 
secretory granules of neutrophil granulocytes. Actually, the highest 
concentration of LF (up to 7 g/L) can be found in the first milk of human 
mothers, the colostrum. (Rodriguez-Franco et al., 2005) As a major 
compound of the human colostrum, LF provides a quickly established first line 
defense of the newborn’s immune system, which serves to protect the infant 
from dangerous pathogens and fight against infections. (Goldman, 1977) 
However, LF levels progressively decrease within the first few days after birth 
until they even out at average concentrations between 1 – 2 g/L in mature 
milk after 5 months. (Reddy et al., 1977) The concentrations of LF in other 
body fluids range from approximately 8 mg/L in saliva, 1.4 g/L in tears to 0.5 
g/L in seminal plasma. (Haupt and Baudner, 1973) In secretory granules of 
neutrophils LF is present to an extent of 15 µg/106 cells. (Bennett and 
Kokocinski, 1978)  
Human LF is composed of 711 amino acids and consists of two symmetrical 
iron-binding lobes. (Anderson et al., 1987) It belongs to the family of 
transferrins and is closely related to human serum transferrin (TF) which in 
turn is mainly responsible for iron (Fe3+) binding and transport within the 
human body. However, LF is not only able to bind Fe2+ and Fe3+ ions, but also 
other metallic cations like Zn2+, Cu2+ or Mn2+. (van der Strate et al., 2001) The 
most prominent form, which can 
be found in milk and leukocytes, is 
positively charged and has a more 
basic isoelectric point (pI) of  8.7 
(Moguilevsky et al., 1985) in 
comparison to mono- and diferric 
TF with pI of 5.6 and 5.2 
respectively. (Hovanessian and 
Awdeh, 1976) If LF is loaded with 
two iron ions, it is called holo-
lactoferrin (depicted in figure 3). 
Although the iron-free form of 
human LF called apo-lactoferrin 
Fig. 3.: Holo-lactoferrin polypeptide fold, taken from 
(Baker and Baker, 2009) – N and C termini are labelled 
with N and C respectively. N and C terminal lobes are 
subdivided in 2 domains each, denoted as N1, N2 and 
C1, C2. The helix linker region is indicated in turquoise 
(H) and iron ions are depicted in red. 
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has a higher affinity for iron than serum TF (Ainscough et al., 1980), the latter 
one seems to be sufficient for iron transport since LF knockout mice show 
completely normal iron homeostasis. (Ward et al., 2003) Concerning the pH 
stability of iron-TF and iron-LF complexes, the former is less stable. TF is 
releasing its two iron molecules between pH 7.0 (Moguilevsky et al., 1985) 
and 5.5 (Mazurier and Spik, 1980), while LF is rejecting its first Fe3+ around 
pH 5.0 and its second at pH 3.5. (Moguilevsky et al., 1985)  
According to basic local sequence alignment algorithm (NCBI - BLAST) not 
only are LF and TF highly conserved among many species, but in addition 
human LF is nearly identical to human TF on the protein level. Moreover, the 
two iron-binding lobes of LF are also virtually identical to each other. These 
data strongly suggest that LF arose from a gene duplication, which was 
already evidenced. (Park et al., 1985)  
The gene expression of LF is estrogen responsive, indicated by the upstream 
steroid factor 1 (SFRE) and estrogen response elements (ERE). Since 
estrogen plays a critical role throughout female’s life, LF levels are reasonably 
regulated in this way. (Teng et al., 2002) Hormone dependent regulation of LF 
gene expression is additionally reflected by the fact that contraceptives 
influence breast milk LF levels. (Lonnerdal et al., 1980) Moreover, the 
expression of the LF gene has been shown to be stimulated by the innate 
immune system. (Li et al., 2009) Besides, another shorter isoform of LF can 
be generated by alternative transcription. It is called delta lactoferrin (ΔLF) 
and lacks the first exon which contains the 5’-untranslated region and the 
signal sequence which is comprised of amino acids 1-19. (Siebert and Huang, 
1997) Consequently, ΔLF demonstrates different localization patterns than 
LF. (Goldberg et al., 2005) Moreover, its expression is altered in different 
breast cancer cells (Benaissa et al., 2005) probably resulting from the fact that 
ΔLF was shown to play a role in regulation of cell cycle progression. (Breton 
et al., 2004)  
Once LF is ingested it is ultimately processed by several proteases within the 
digestive system, predominantly pepsin, trypsin and chymotrypsin. Upon 
proteolysis by trypsin or chymotrypsin the two iron binding lobes can be 
separated. (Bluard-Deconinck et al., 1978) If LF is digested by pepsin, a small 
bioactive fragment called lactoferricin (LFcin) is released (Kuwata et al., 
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1998), which holds true for pepsin-mediated 
hydrolysis of bovine (Bellamy et al., 1992a) and 
human (Yamauchi et al., 1993) LF. LFcin 
(depicted in figure 4) consists of the first 45 - 50 
amino acid residues cleaved from the N-terminus 
of LF. (Gifford et al., 2005) Yet, the actual length 
of LFcin is controversial throughout literature, 
meaning that it ranges between amino acids 1-
49, 1-45, 20-47, 19-36, 20-38 of the full-length 
protein. Nevertheless the functionality of this 
bioactive peptide(s) is indisputable, which is 
prevalently its anti-pathogenic activity against a 
wide variety of bacteria, fungi and viruses. 
(Chapple et al., 1998; Wakabayashi et al., 2003) 
Indeed, LFcin seems to be even more effective than full-length LF concerning 
anti-pathogenicity. (Farnaud et al., 2004)  
Both LF and LFcin bear potent antimicrobial activity towards various kinds of 
bacteria, in particular gram-negative ones like Escherichia coli, Pseudomonas 
aeruginosa, Samonella typhimurium, or Yersinia enterocolitica, but as well 
gram-positive ones like Staphylococcus aureus, Streptococcus mutans, 
Listeria monocytogenes or Clostridium difficile. (Bellamy et al., 1992a) It is a 
widely accepted fact that full-length LF is inhibiting the bacterial growth by 
means of iron sequestration (Oram and Reiter, 1968), nonetheless other 
studies implicated additional mechanisms. (Arnold et al., 1982) LFcin is able 
to effectively neutralize the major endotoxin of gram-negative bacteria, 
namely lipopolysaccharide (LPS). In particular, the first six amino acids 
(GRRRRS) are most crucial in inhibiting LPS action. (Zhang et al., 1999) 
Another mechanism how LFcin is exerting its antimicrobial action is impelling 
the permeabilization of bacterial membranes. (Aguilera et al., 1999) Recent 
publications revealed that an additional bioactive peptide derived from the N-
terminal half of LF contains a LFcin-like structure which imparts antibacterial 
activity. It is called lactoferrampin (LFampin) and is comprised of sequences 
between amino acids 260-285 which are similar to amino acids 21-49 of the 
full-length protein. (Adao et al., 2011; Haney et al., 2009)  
Fig. 4.: Biological assembly of 
human LFcin, taken from (Hunter 
et al., 2005) – Overlay of lowest 
energy conformations of human 
LFcin obtained from NMR 
spectroscopy data. 
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Furthermore, LF displays antiviral activity against several RNA and DNA 
based viruses (van der Strate et al., 2001) including Herpes Simplex Virus 
(HSV) (Andersen et al., 2003), Cytomegalie Virus (CMV) (Beljaars et al., 
2004), human Papilloma Virus (HPV) (Mistry et al., 2007) and human 
Immunodeficiency Virus (HIV). (Zuccotti et al., 2007) LF prevents initial 
binding of the virus to host cells by competing for the docking receptors used 
by viruses in order to enter a cell. Consequently, these adsorbance molecules 
e.g. heparan sulfate or glycosaminoglycans are blocked and no longer 
accessible for the virus. (Andersen et al., 2003; Andersen et al., 2001) 
Additionally, LF and LFcin can directly bind Hepatitis C Virus (HCV). In case 
of rotaviruses, LF might inhibit viral replication inside host cells. (Superti et al., 
1997) 
Regarding antifungal activity, LF is known to inhibit the growth of e.g. Candida 
albicans by sequestration of iron. (Kirkpatrick et al., 1971) Obviously, LF in 
addition upregulates the host defense by activating neutrophils which in turn 
combat the fungal infection. (Ueta et al., 2001) Besides, LFcin can directly 
target and kill fungi via the membrane interaction as it was shown for bacteria. 
(Bellamy et al., 1993)  
Moreover, LF is inhibiting the parasitic growth by means of iron depletion but 
also the iron-saturated form or N-terminal derived peptides of LF demonstrate 
antiparasitic activity, suggesting additional mechanisms. (Fritsch et al., 1987; 
Turchany et al., 1995) 
Asides the antimicrobial effect, LF and LFcin demonstrate anti-tumor activity. 
(Yoo et al., 1997) For instance, it has been shown that LF inhibits tumor 
growth (Bezault et al., 1994) and tumor-induced angiogenesis. (Shimamura et 
al., 2004) Additionally, human LF attracts anti-carcinogenic NK cells and CD8+ 
T lymphocytes. (Wang et al., 2000) Combined with conventional 
chemotherapy LF enhances positive effects on patients’ treatment. 
(Varadhachary et al., 2004) In case of LFcin, it was shown to force tumor cells 
into apoptosis. (Mader et al., 2005) In general, LFcin is thought to be 
especially effective in accomplishing its antimicrobial and anti-tumor tasks 
because of its highly positive net charge. (Yang et al., 2004)  
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3. Objectives:  
 
The aim of the study was to characterize the binding of human LF to human 
Plg. Via mass spectrometric analysis LF was initially revealed as a novel 
interaction partner of M6P/IGF2R. Since M6P/IGF2R was known to cooperate 
with components of the fibrinolytic system from previous studies (Leksa et al., 
2002), Plg was discovered as an additional interaction partner of LF. 
Therefore, the identification of molecular determinants responsible for specific 
binding of LF to Plg obtained priority in the following work. One key 
mechanism how Plg and respectively Plm is binding its partners is via C-
terminal lysines of target proteins. (Holvoet et al., 1986) Since LF provides a 
C-terminal lysine, our main focus was directed on the interaction of Plg and 
LF’s C-terminus. Ultimately, functional consequences resulting from the 
interaction of the two molecules were examined. 
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4. Materials and Methods: 
4.1. Materials: 
Tris, glycine, NaCl, NaHCO3, 32% HCl, 2-propanol, glycerol, acrylamid 
Rotiphorese Gel 30, LB-agar (Luria/Miller), BSA were purchased from Roth, 
Karlsruhe, Germany. Agarose LE was bought from Biozym Scientific, 
Hessisch Oldendorf, Germany. Protease inhibitor cocktail tablets were 
obtained from Roche Applied Science, Penzberg, Germany. The chromogenic 
Plg substrate S-2251 was obtained from Coachrom Diagnostica, Vienna, 
Austria. Aminocaproic acid (6-ACA), imidazole, tricine, hydroxylamine 
hydrochloride, methanol, acetic acid, tetramethylethylenediamine (TEMED), 
10 % ammonium persulfate (APS), RPMI 1640, LF from human milk L0520 
were purchased from Sigma-Aldrich, St.-Louis, MO, USA. Ethidiumbromide as 
well as all DNA modifying enzymes and related buffers were purchased from 
Fermentas (ThermoFisher Scientific), Waltham, MA, USA. The LF derived 
peptides were synthesized by Peptide 2.0, Chantilly, VA, USA. Plg (purified 
Glu-Plg) was obtained from Technoclone, Vienna, Austria. Biotin was 
obtained from Pierce and trypsin-EDTA, L-glutamine, penicillin and 
streptomycin from Invitrogen, Carlsbad, CA, USA. The PVDF membranes 
were purchased from Millipore, Billerica, MA, USA. Human LF cDNA 
NM_002343.3 (SC118685) in the pCMV-XL5 vector was obtained from 
OriGene, Rockville, MD, USA 
 
4.2. Buffers: 
LB medium: 40 g/L LB agar – autoclave! 
50x TAE buffer: 2 M Tris.HCl, 0.05 M EDTA + 57.1 ml Glacial acetic acid / 1 L 
1x TAE buffer: 100 ml 50x TAE + 900 ml dH2O 
5x KCM buffer: 0.5 M KCl, 0.15 M CaCl2, 0.25 M MgCl2 
Miniprep buffer P1: 50 mM Glucose, 25 mM Tris.HCl, 10 mM EDTA, pH 8.0 
Miniprep buffer P2: 0.2 M NaOH, 1% (w/v) SDS 
Miniprep buffer P3: 5 M Potassium acetate (60ml), 11.5ml Glacial acetic acid 
ad 100 ml with dH2O, pH 5.5 
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Lysis buffer: 20 mM Tris.HCl, 140 mM NaCl, pH 8.2, 1% Nonidet P-40, add 1 
protease inhibitor tablet (Roche cOmplete Protease Inhibitor Cocktail) per 30-
50 ml  
Anode buffer for BN-PAGE: 25 mM Imidazole.HCl pH 7.0 
Cathode buffer (CB) for BN-PAGE: 50 mM Tricine, 7.5 mM Imidazole.HCl pH 
7.0 
Deep blue cathode buffer for BN-PAGE: CB + 0.02% CBB G250 
Slightly blue cathode buffer for BN-PAGE: CB + 0.002% CBB G250 
Sample buffer for BN-PAGE: 5 % Coomassie Brilliant Blue in 0.5 M 6-ACA 
10x running buffer for BN-PAGE: 250 mM Tris.HCl, 1920 mM Glycine 
10x Western blotting buffer for BN-PAGE: 250 mM Tris.HCl, 1920 mM Glycine  
Coupling buffer: 0.1 M NaHCO3, 0.5 M NaCl 
Washing buffer: 20 mM Tris.HCl pH 9.3 
Elution buffer: 20 mM Tris.HCl pH 11.7 
Running gel buffer: 1 M Tris.HCl, pH 8.8, 0.27 % SDS  
Stacking gel buffer: 1 M Tris.HCl, pH 6.8, 0.8 % SDS  
10x running buffer (10x ELFO): 250 mM Tris.HCl, 1920 mM Glycine, 0.1 % 
SDS - don’t adjust pH, it will be 8.3 after dilution! 
1x running buffer (1x ELFO): 100 ml 10x ELFO + 900 ml dH2O 
10x Western blotting (WB) buffer: 250 mM Tris.HCl, 1920 mM Glycine. 
1x WB buffer: 100 ml 10x WB buffer + 200 ml methanol ad 1 L with dH2O 
10x TBS: 20 mM Tris.HCl, 1.38 M NaCl, pH 7.6 
TBST: 100 ml 10x TBS ad 1 L with dH2O + 1 ml Tween 20® 
FACS buffer: 1x PBS, 1 % BSA, 0.02 % NaN3 
Solutions for silver staining: 
- Fixing solution: 30% ethanol, 10% acetic acid  
- Stop solution: 5% acetic acid  
- Ethanol wash: 10% ethanol  
Biotin labeling buffer: 0.1 M NaHCO3, 0.1 M NaCl pH 8.4 
 
4.3. Antibodies: 
The biotinylated rabbit anti-human LF polyclonal antibody (LFb, ab25811) was 
purchased from Abcam and mouse anti-human LF monoclonal antibodies 
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(mAbs) 1D5, 4C5, 3D5 and 4E2 (each used 1:1000) were kindly provided by 
Dr. Otto Majdic from the Institute of Immunology, Centre for Pathophysiology, 
Infectiology and Immunology, Medical University Vienna. The mouse anti-
human Plg mAb (clone 7Pg) was obtained from Technoclone, Vienna. Anti-
mouse IgG antibody conjugated to horseradish peroxidase (HRP) produced in 
rabbit (used 1:50000) was bought from Sigma Aldrich. The Streptavidin-
biotinylated horseradish peroxidase complex (used 1:3000) was purchased 
from GE Healthcare, UK. 
 
4.4. Cell culture: 
The human monocytic cell line THP-1 from ATCC and the human kidney 
epithelial tumor cell line TCL-598 were a gift from the Novartis Research 
Institute, Vienna, Austria. The cells were cultivated in RPMI 1640 medium with 
10% heat inactivated fetal calf serum (FCS), supplemented with 2 mM L-
glutamine, 100 units/ml penicillin and 100 units/ml streptomycin. For the Plg 
activation assay the cells were seeded in serum-free medium in order to avoid 
bovine serum Plg contamination. The cells were maintained at 37°C with 5 % 
CO2 and passaged twice a week using trypsin-EDTA.  
 
4.5. Cloning of human LF: 
Bacterial cells:  
E.Coli DH5α: fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17   
 
Cloning strategy:  
The cDNA of human LF NM_002343.3 (SC118685) in the pCMV-XL5 vector 
was obtained from OriGene, Rockville, MD, USA. The sequencing reactions 
and synthesis of primers were accomplished by Eurofins MWG, Ebersberg, 
Germany. Three forward primers (fw) were designed to introduce a HindIII 
restriction enzyme cleavage site on the N-terminal end of the generated PCR 
products. Forward primer 3 was used to produce ΔLF, another isoform of LF 
which lacks the first 44 amino acids of the full length protein. Five reverse 
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primers (rev) were designed to introduce a NotI cleavage site at the C-
terminal end, and one reverse primer (rev2) to introduce a point mutation and 
thus changed the C-terminal amino acid from lysine to threonine. Three of the 
reverse primers should have generated truncated versions of the protein. The 
primer sequences are highlighted in appendix 1 (section 8.1. DNA sequence 
of human LF) and listed in table 1 with restriction sites underlined. The cDNA 
after PCR amplification were to be subcloned into pGEMT (or pBKS-) and 
afterwards ligated into the pBMN-Z vector backbone (pBMN), which is 
suitable for expression in mammalian cells.  
 
4.6. Transformation of chemically competent bacteria: 
Heat shock transformation: 
- Mix 10-100 ng of plasmid with 100 µl of RbCl2 competent DH5α 
- Incubate 30’ on ice 
- Heatshock for 90 sec. on 42°C and put back on ice for 2’ 
- For recovery, add 300 µl fresh LB and incubate for 1 h at 37°C while 
shaking 
- Plate on LB + amp (100 µg/ml) & incubate o/n at 37°C 
- Inoculate a single colony in 3-5 ml LB + amp o/n at 37°C while shaking 
 
KCM transformation: 
- Mix 80 µl KCM competent bacteria + 20 µl 5x KCM Buffer + 1-10 ng 
plasmid  
- Incubate 10’ on ice 
- Incubate 10’ at RT 
- Add 1 ml LB and incubate 1 h at 37°C while shaking 
- Plate 100 µl on LB + amp (100 µg/ml) and incubate o/n at 37°C 
 
4.7. Plasmid preparation (mini prep): 
- Inoculate a single colony in 3-5 ml LB + amp (100 µg/ml) o/n at 37°C 
constantly shaking 
- Spin down bacteria for 2’ at 14.000 rpm 
A novel interaction partner of plasminogen in regulation of fibrinolysis       Alexander Zwirzitz  
 20 
- Add 200 µl buffer P1 + 20 µg/ml RNase A and resuspend 
- Add 200 µl buffer P2, mix by inverting the tube 4-6x & incubate 5’ at RT 
- Add 200 µl buffer P3, mix by inverting the tube 4-6x 
- Spin 15’ at 14.000 rpm  
- Transfer the supernatant to a new tube 
- Add 500 µl isopropanol and mix by inverting the tube 4-6x 
- Spin 20’ at 14.000 rpm and decant supernatant  
- Wash pellet with 70% EtOH 
- Spin 3’ at 14.000 rpm & remove supernatant 
- Air-dry and resuspend in 30-50 µl dH2O 
 
4.8. Maxi prep:  
Dilute overnight culture 1:100 and grow at 37°C o/n while shaking. Then 
follow NucleoBond Xtra (Macherey-Nagel) protocol. 
 
4.9. PCR reactions:  
Phusion® polymerase protocol: 
 
dH2O 11.8 µl   denaturating 98°C 30’’  
5x HF-buffer 4 µl   denaturating 98°C 10’’   
10 mM dNTPs 0.4 µl   annealing 64°C 30’’ 35 cycles 
10 µM primer fw 1 µl   elongation 72°C 35’’   
10 µM primer rev 1 µl   final extension 72°C 7’  
template DNA (20 ng/µl) 1 µl        
Phu polymerase (2 u/µl) 0.2 µl       
DMSO 0.6 µl        
 
[DMSO is added to reduce unspecific binding and can be omitted] 
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Taq polymerase protocol: 
10x buffer 5 µl  denaturating 98°C 2'  
10 mM dNTPs 1 µl  denaturating 98°C 30’’   
10 µM primer fw 2.5 µl  annealing 64°C 30’’ 35 cycles 
10 µM primer rev 2.5 µl  elongation 72°C 2.5''   
template DNA (270 ng/µl) 1 µl  final extension 72°C 10’  
Taq polymerase (5 u/µl) 0.5 µl      
MgCl2 (25 mM) 4 µl      
H2O 33.5 µl      
 
Touchdown PCR protocol: 
Reaction mix is identical to Phusion® polymerase protocol. Annealing 
temperature is decreased by 1°C every 3 cycles for 12 cycles, and then run 
25 cycles with 66°C. 
 
denaturating 98°C 30’’ 
denaturating 98°C 10’’ 
annealing 70 - 67°C 30’’ 
elongation 72°C 35’’ 
final extension 72°C 7’ 
 
4.10. Agarose gel electrophoresis: 
For the analysis of DNA, 0.8% agarose gels were used in the ‘PerfectBlue 
Gelsystem Mini M’ apparatus from Peqlab, Germany. 
- Mix 0.64 g agarose + 80 ml 1x TAE buffer 
- Heat 2-3 min in the microwave 
- Let cool down, add 3 µl EtBr (10 mg/ml) and pour the gel 
The gel was run constantly at 120 V for 20-45 min, depending on the size of 
observed fragments. 
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4.11. Elution of PCR products from an agarose gel: 
According to instructions of PROMEGA Wizard SV gel & PCR clean-up kit. 
The principle of the kit is based on the DNA binding capacity of membranes 
within special tubes. Centrifugation removes melted agarose and other 
contaminating molecules like proteins for example, while DNA remains bound 
to the membrane and can be eluted as a final step. 
 
4.12. Ligation reactions: 
Calculate amount of insert:  
 ng vector x bp insert 
ng of insert =  
 bp vector 
 
 
x = (50 ng pBKS x 2430 bp insert) /2950 bp pBKS = 41 ng 
Use a 10:1 ratio (recommended 1:10 to 10:1) 
 
Reaction mix: 
5x ligation buffer 4 µl 
vector  50 ng 
insert  x ng 
T4 ligase (5 u/µl) 1 µl 
dH2O ad 20 µl 
 
- Put on 4°C (recommended 12 - 16°C) o/n  
- Transform DH5α with 5 or 10 µl ligation mixture 
- Blue/white screening for positive clones:  
- add 100 µl of 100 mM IPTG and 20 µl of 50 mg/ml X-gal per plate ½ h 
before plating the bacteria, incubate plate o/n at 37°C 
- Pick white colonies & inoculate in 5 ml LB+amp o/n at 37°C while shaking  
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4.13. Restriction enzyme digestion:  
Incubate the following reaction mix for 2 h at 37°C: 
10x buffer R 2 µl 
DNA 1 µg 
10 u/µl restriction enzyme 1 (HindIII ) 0.5 µl 
10 u/µl restriction enzyme 2 (NotI ) 2 µl 
dH2O ad 20 µl 
 
The amount of restriction enzyme used was calculated by the DoubleDigest™ 
tool on the Fermentas homepage. The samples were directly loaded on an 
agarose gel and the corresponding bands were cut out and eluted. 
 
4.14. In vitro proteolysis of human LF: 
Coupling of proteases to beads: 
- Incubate CNBr-activated sepharose beads (1 ml) in 3 mM HCl (10 ml) 
for 15 min. at RT 
- Wash 2-3 times with 1x Coupling buffer (~20 ml) 
- Incubate beads in a 2 ml Eppendorf tube with 1 ml protease (2 mg/ml) 
in 1x Coupling buffer for 2 h at RT permanently shaking 
- Stop the coupling reaction by blocking remaining active groups with 50 
mM glycine for 1 h at RT constantly shaking 
- The beads can be stored in PBS or in FACS buffer (long-term storage) 
 
Enzymatic digest: 
- Add 50 µg LF to 100µl (protease coupled) beads and add 850 µl of 
0.035 M NaCl or PBS in a 2 ml Eppendorf tube  
- Adjust pH to enzymes’ optimum (pepsin: pH ~2-3, trypsin: pH~8) 
- Incubate at 37°C while constantly shaking 
- Take aliquots at indicated time points, readjust pH and store at -20°C 
- Add 10 µl 4x non-reducing SDS sample buffer to 30 µl of aliquots and 
use for SDS-PAGE  
 
A novel interaction partner of plasminogen in regulation of fibrinolysis       Alexander Zwirzitz  
 24 
4.15. Design of LF-derived peptides: 
I designed 4 peptides derived from human LF. Peptide #1 (pLF1) is designed 
in order to mimic human LFcin and therefore it is comprised of the amino 
acids 20-38 of human LF. The peptide #2 (pLF2) is built up from the amino 
acids 283-301 of human LF. It contains a C-terminal lysine which could 
possibly be exposed upon trypsin digestion of LF. Furthermore, peptide #2 
covers parts of human LFampin. The peptide #3 (pLF3) is created to 
encompass the very C-terminus of human LF, so it is made up of the last 19 
amino acids – 693-711. Peptide #4 (pLF4) is a scrambled peptide which 
serves as control. It is comprised of the same amino acids as peptide #3 but 
randomly arranged. The peptides were created in such a way that they show 
a similar secondary structure. All the peptides were subjected to the 
consensus secondary structure prediction server NPS@ of the Institute of 
biology and chemistry of proteins (ICBP), Lyon, France and the PEP-FOLD de 
novo peptide structure prediction server. The peptides 1-3 are highlighted in 
appendix 2 (section 8.2. protein sequence of human LF) and listed in table 2. 
 
4.16. Cell lysis: 
- Lysis works best with approximately 1.5x106 cells per ml  
- Wash cells with PBS  (centrifuge suspension cells at 2000 rpm for 5 
min) 
- Lyse cells in 75 µl lysis buffer 20 min on ice 
- Remove debris by spinning down the lysate at 13000 rpm for 2 min  
- Transfer the supernatant to a new tube and store at –20°C or use  
directly 
 
4.17. Purification of M6P/IGF2R from cell supernatants: 
- Anti M6P/IGF2R antibody (MEM238 or MEM240) was coupled to 
sepharose CNBr beads as described for proteases in 4.14, which were 
afterwards filled in a column 
- Wash column 2x  with PBS 
- Load the lysate (see 4.16.) of THP-1 cells 3x serially  
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- Apply 1 ml washing buffer (pH 9.3)  
- Apply 2x 1 ml elution buffer (pH 11.7)  
- Apply 1 ml elution buffer the 3rd time + resuspend column with a cut tip 
- Apply 2 ml elution buffer  
- Wash once with PBS and once with FACS buffer 
- Store the column in FACS buffer and freeze the fractions 
 
Aliquots (75 µl) were taken for electrophoresis after each washing or elution 
step. 
 
4.18. Binding assays: 
- Dilute all molecules in PBS  
- Coat Falcon® flexible 96-well PVC plates (Becton Dickinson) with 250 
ng (50 µl of 5 µg/ml) protein at 37°C for 2 h 
- Add 50 µl 2 % BSA to yield a final concentration of 1 % BSA in order to 
block free binding sites of the wells for 1 h at RT 
- Wash the wells 4 - 5 times with 1x PBS  
- [In competition binding assays: dilute assayed molecules in PBS with 
0.1% Triton X-100 and optionally pre-incubate additional (competing) 
molecules for 30 min on ice] 
- Add 1 µg (50 µl of 20 µg/ml) or indicated concentrations of assayed 
molecules to the wells and incubate from 2 h to overnight at 4°C 
- Wash the wells 4 - 5 times with chilled 1x PBS  
- To release the bound molecules, add 10 µl of 1x non-reducing SDS-
PAGE sample buffer to the wells  
- Use either directly for SDS-PAGE or store at -20°C 
 
4.19. SDS polyacrylamide gel electrophoresis (SDS-PAGE): 
Electrophoresis was performed with the ‘PerfectBlue Dual Gel System Twin’ 
apparatus from Peqlab, Germany. 
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- Mix the ingredients according to the table below in order to yield the 
desired quantity and percentage of running gels  
- Add 10% APS and TEMED in the end to start the polymerization 
reaction 
 
Total volume 10.00 20.00 30.00 40.00 ml 
1% 1 gel 2 gels 3 gels 4 gels  
Acrylamid 0.33 0.66 0.99 1.32 ml 
Tris buffer 8.8 3.75 7.50 11.25 15.00 ml 
H20 5.92 11.84 17.76 23.68 ml 
APS 10% 100.00 200.00 300.00 400.00 µl 
TEMED 8.00 16.00 24.00 32.00 µl 
      
6%      
Acrylamid 1.98 3.96 5.94 7.92 ml 
Tris buffer 8.8 3.75 7.50 11.25 15.00 ml 
H20 4.27 8.54 12.81 17.08 ml 
APS 10% 100.00 200.00 300.00 400.00 µl 
TEMED 8.00 16.00 24.00 32.00 µl 
      
7.5%      
Acrylamid 2.48 4.95 7.43 9.90 ml 
Tris buffer 8.8 3.75 7.50 11.25 15.00 ml 
H20 3.78 7.55 11.33 15.10 ml 
APS 10% 100.00 200.00 300.00 400.00 µl 
TEMED 8.00 16.00 24.00 32.00 µl 
      
10%      
Acrylamid 3.30 6.60 9.90 13.20 ml 
Tris buffer 8.8 3.75 7.50 11.25 15.00 ml 
H20 2.95 5.90 8.85 11.80 ml 
APS 10% 100.00 200.00 300.00 400.00 µl 
TEMED 8.00 16.00 24.00 32.00 µl 
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12.5%      
Acrylamid 4.13 8.25 12.38 16.50 ml 
Tris buffer 8.8 3.75 7.50 11.25 15.00 ml 
H20 2.13 4.25 6.38 8.50 ml 
APS 10% 100.00 200.00 300.00 400.00 µl 
TEMED 8.00 16.00 24.00 32.00 µl 
      
15%      
Acrylamid 4.95 9.90 14.85 19.80 ml 
Tris buffer 8.8 3.75 7.50 11.25 15.00 ml 
H20 1.30 2.60 3.90 5.20 ml 
APS 10% 100.00 200.00 300.00 400.00 µl 
TEMED 8.00 16.00 24.00 32.00 µl 
      
17.5%      
Acrylamid 5.78 11.55 17.33 23.10 ml 
Tris buffer 8.8 3.75 7.50 11.25 15.00 ml 
H20 0.48 0.95 1.43 1.90 ml 
APS 10% 100.00 200.00 300.00 400.00 µl 
TEMED 8.00 16.00 24.00 32.00 µl 
 
- Pour the solution in the casting chamber  
- Overlay the gel with some drops isopropanol  
- Let polymerize for 20 min  
- Pour off isopropanol and get rid of remaining alcohol with a thin filter 
paper 
- Prepare the stacking gel solution by mixing: (recipe for 1 gel)  
• 0.66 ml acrylamid,  
• 0.63 ml stacking gel buffer  
• 3.66 ml dH2O  
 (can be done in parallel with mixing the running gel)  
- Then add 50 µl 10 % APS and 5 µl TEMED per stacking gel 
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- Pour the stacking gel onto the running gel and insert a comb with the 
appropriate number of wells while avoiding formation of air bubbles 
underneath the comb 
- Let polymerize for 20 min, then remove the comb and clean the wells 
properly  
- Place the casting chambers into the running device and fill up with 1x 
ELFO buffer, then the gel is ready for loading 
- Boil the samples for 2 - 5 min at 95°C before loading 
Run the gel constantly at 90 V, until the samples reach the running gel 
(approximately 20 - 30 min), then increase the voltage to 140 V until the 
running front reaches the end of the gel 
 
4.20. Blue native polyacrylamide gel electrophoresis (BN-PAGE): 
BN-PAGE was executed according to (Schagger and von Jagow, 1991). 
 
Mix the ingredients according to the recipes depicted below:  
 Stacking Gel Gradient - Running Gel 
 3% 3% 13% 
AA 30% 1.2 ml 1.93 ml 8.73 ml 
3x gelbuffer 4 ml 6.43 ml 5.23 ml 
Glycerol - - 3.18 g 
H2O 6.65 ml 11.5 ml 2 ml 
APS 10% 110 µl 107 µl 78.6 µl 
Temed 10 µl 10.8 µl 7.86 µl 
 
Glycerol is added to the 13% gel-mixture to establish the gradient. It 
guarantees a better blending of the two gel-mixtures within the gradient mixer. 
The 3-13% gradient gel was prepared with a gradient mixer (lower percentage 
in back, higher percentage in front chamber), a 3% stacking gel was poured 
on top. After polymerization, it was placed in the running apparatus and 
equilibrated at 4°C in the cold room. Anode buffer was poured into the lower 
chamber and any remaining air bubbles were removed with the help of a 
syringe. Then the slots were slightly filled with (colorless) cathode buffer and 
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samples were loaded in the cold room. The upper chamber was filled with 
deep blue cathode buffer and electrophoresis was conducted at 80 V for 4 h 
until the samples had reached the running gel at least. Then the voltage was 
set to 120 V overnight. In the next 
morning, deep blue cathode buffer was 
exchanged to slightly blue cathode buffer 
until the run was completed (another 2-4 
h). The individual lanes were cut out and 
either directly used in a 2nd dimension 
SDS-PAGE or frozen. As marker, ferritin 
(dimer at 880 kDa and monomer at 440 
kDa) and jack bean urease (trimer at 272 
kDa) were used. In case of 2nd dimension 
SDS-PAGE (see figure 5), the 
corresponding lane was placed on top of 
a common SDS-PAGE gel with a 
specially modified comb without single 
slots and the gel was run as described in section 4.19. 
 
4.21. Western blot: 
Western blotting was performed with the ‘PerfectBlue Semi-Dry Electro 
Blotter’ from Peqlab, Germany and the Immobilon-P™ PVDF Membranes 
from Millipore, USA. 
 
- Soak the PVDF membrane in methanol (MeOH) for 1 min 
- Pre-wet the membrane and 2 pieces of 3 mm Whatman filter papers in 
1x WB buffer 
- Assemble blotting sandwich in the following manner (anode - cathode): 
• 3 mm Whatman filter paper (anode) 
• PVDF membrane 
• Gel 
• 3 mm Whatman filter paper (cathode) 
- Wipe out air bubbles carefully by rolling a plastic pipette 
Fig. 5. BN-PAGE 2nd dimension scheme,  
taken from Science Signaling, 25 July 2006 
Vol 2006, Issue 345 – Individual BN-PAGE gel 
stripes were cut out, rotated 90° 
counterclockwise and placed on top of the 2nd 
dimension SDS-PAGE gel, which separates 
individual proteins from their conserved 
protein complexes. 
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- Close the apparatus, tighten the screws evenly moderate and run with 
20 V limited to 400 mA for 1 h 
- Block free binding sites on the membrane with 5% non-fat dry milk for 1 
h at RT while constantly shaking  
- Rinse the membrane once and wash it 2 - 3 times with TBST for 5 min 
 
Immunodetection: 
- Incubate the membrane with an adequate primary antibody for 1 h at 
RT while constantly shaking 
- Wash the membrane 3 times for at least 5 min with TBST 
- Incubate the membrane with a secondary antibody HRP-conjugate 
suitable to the primary antibody for 1 h at RT while constantly shaking 
- Wash the membrane 3 times for at least 5 min with TBST 
- Place the membrane within a plastic foil or bag, add a 1:1 mix of 
substrate and luminol enhancer from the ‘ChemiGlow® West 
Chemiluminescence Substrate Kit’ (from Cell Biosciences - Santa 
Clara, California)  
- Distribute the solution well all over the membrane and get rid of excess 
liquid and any air bubbles by wiping the foil carefully with a paper towel 
- Analyze the Western blot with the Fujifilm ImageQuant LAS-4000 CCD 
camera system and Multi-Gauge software 
 
4.22. Silverstaining of SDS-PAGE gels: 
(According to Pierce® Silver Stain Kit for Mass Spectrometry) 
 
- Wash a gel twice with dH2O water for 5 min  
- Decant water and incubate the gel twice for 15 min at RT in the fixing 
solution  
- [The gel may remain in fixing solution overnight without affecting the 
stain performance] 
- Wash the gel twice with ethanol and twice with dH2O for 5 min each  
- Just before use, prepare sensitizer working solution (1 part Silver Stain 
Sensitizer + 500 parts dH2O) 
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- Incubate the gel in sensitizer working solution for exactly 1 min, then 
wash twice with dH2O for 1 min  
- Mix 1 part Silver Stain Enhancer with 100 parts Silver Stain, 
immediately add it to the gel and incubate the gel for 5 min 
- Quickly wash the gel twice with dH2O for 20 seconds  
- Immediately add developer working solution (1 part Silver Stain 
Enhancer with 100 parts Silver Stain Developer) and incubate until 
protein bands appear (optimal signal vs. background 2 - 3 min)  
- When the desired band intensity is reached, replace developer working 
solution with stop solution. Wash the gel briefly, then replace acetic 
acid with dH2O and incubate for 10 min 
 
4.23. Dot far Western blot: 
- Soak a piece of PVDF membrane for several seconds in MeOH  
- Rinse membrane with 1x WB buffer 
- Assemble the dot blotting sandwich in the following manner:  
• PVDF membrane (top) 
• 1 mm Whatman paper 
• 3 mm Whatman paper 
• paper towel (bottom) 
- Directly apply samples in a small volume (0.5 - 2 µl) with a pipette  
- Let the membrane bind the protein/peptide samples for 5 - 15 min but 
do not let the membrane dry completely. 
- Block remaining binding sites with 5 % non-fat dry milk for 1 h at RT 
while constantly shaking 
- Wash the membrane 3 times for 5 min at least with TBST 
     [Skip the following 2 steps when performing a Western dot blot] 
- Incubate the membrane with the assay molecule solution (1 µg/ml in 
TBST) for 1 – 2 h or o/n at 4°C while constantly shaking 
- Wash the membrane 3 times for at least 5 min with TBST  
- Continue with immunodetection (of bound assay molecules) as 
described in 4.21. Western blot 
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4.24. Biotin-labeling of antibodies: 
- Dialyze 1 mg purified antibody using biotin labeling buffer at 4°C o/n 
- Add 100 µg biotin (dissolved in DMSO) per mg of antibody 
- Incubate 1.5 h at RT while rotating 
- Stop coupling reaction by addition of 10% (of total volume) 1.5 M 
hydroxylamine pH 8.5 
- Remove unbound biotin by dialysis in PBS at 4°C o/n  
- Add a preservative like 0.02% NaN3 (inhibits HRP) or 0.01% thimerosal 
 
4.25. Plg activation assay: 
- Seed 50.000 TCL cells/well in serum-free RPMI 1640 in a 96-well plate 
24h before the assay  
- Incubate 100 nM Plg, 5 µg/ml α2AP, 1.6 mM chromogenic Plg 
substrate (S-2251) and indicated assayed molecules (10 nM TA, 20 
µg/ml LF, pLFs) together for 30 min on ice  
- Wash the cells 2x with serum-free medium  
- Add 50 µl of serum-free medium and 50 µl of the incubated mix to each 
well (avoid air bubbles!) 
- Measure absorption at 405 nm every hour using an enzyme-linked 
immunosorbent assay reader (Mithras LB 940 platereader from 
Berthold, Bad Wildbad, Germany) 
[Mithras platereader can heat up to 37°C, thus keep the plate inside while 
measuring every hour, 20 mM HEPES has to be included in medium] 
 
4.26. Quantification of Western blotting membranes:  
Densitometric quantification of Western blots was done with the Fujifilm 
Multigauge software. Rectangles of exactly same size were drawn close to 
the boarders of individual bands. In addition, one rectangle per lane was used 
for detection of background signal. The corresponding background signal was 
subtracted from individual bands. From this value the negative control bands 
(always BSA), if present, were subtracted to yield the final quantity value. The 
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amount of emitted chemiluminescence signals was measured in arbitrary 
units (AU) which represent the relative density value of a band. 
 
4.27. Statistical analysis: 
All experiments were performed at least three times (n ≥ 3). Statistical 
analysis was done in Microsoft Excel. For the detection of outliers I used 2 
widely approved tests: first, the Grubbs outlier test, and second, the Dean and 
Dixons Q-test. Both tests considered the same data points as outliers, which 
therefore have been excluded from further calculations. The data are 
expressed as mean values ± S.E.M. (standard error of the mean). 
Significance was assessed via one-way ANOVA followed by Tukeys HSD 
test. P values less than * 0.05, ** 0.01, *** 0.001 were considered as 
significant or highly significant, respectively. 
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5. Results: 
 
5.1. Preliminary data: 
Preliminary data of our group identified LF as a binding partner of 
M6P/IGF2R. Additionally, they indicated that human LF bound to Plg but the 
exact binding site remained unknown. Since Plg is very well known for 
preferably binding C-terminal lysines, we assumed that the attachment to LF 
which offers a lysine at its C-terminus, probably occurred in an analogous 
manner.  
 
5.2. Cloning of LF mutant forms: 
In order to localize a decisive Plg binding region in LF, a first step was to 
clone a C-terminal lysine to threonine mutant and several truncated forms of 
LF, which were supposed to be subsequently analyzed by biochemical 
methods. Plg binds many of its known binding partners via interaction with 
their C-terminal lysines. Should it be with LF as well, the mutation changing 
LF’s C-terminal amino acid lysine to threonine would delete the corresponding 
interaction platform. Since the C-terminal lysine of LF is encoded by AAG, a 
single point mutation, introduced by PCR site-directed mutagenesis, to ACG 
was sufficient to change lysine (K) to threonine (T). If the C-terminal lysine 
was not responsible for interaction with Plg, truncated LF variants would be a 
backup to narrow down the Plg binding region. Albeit I was able to clone the 
desired PCR products (~2200 bp for recombinant full-length LF and LF C-
terminal K to T mutant; ~1400bp for truncated LF) into subcloning vectors e.g. 
pGEMT-easy (see Fig. 5.2.), I could rarely detect colonies after plating of 
bacteria transformed with LF variants ligated into the pBMN expression vector 
backbone. Even if colonies were growing, I could not extract any mammalian 
expression vector (pBMN) containing LF DNA of correct corresponding size. 
Since bacterial promoters might be leaky, functional LF which is able to 
suppress bacterial growth might have been produced, thereby killing positive 
clones. In order to cope with this problem and compensate for one of LF’s 
major antibacterial mechanisms, namely the sequestration of iron, I generated 
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agar plates providing this essential nutrient in excess. However, no colonies 
were detectable. 
 
Figure 5.2. Digest of LF variants ligated into pGEMT-easy backbone: 
Double restriction enzyme digest (HindIII + NotI) of plasmids derived from positively selected 
clones after transformation of E.Coli DH5α with LF PCR products ligated into pGEMT-easy 
vector backbone (~3000 bp). 
 
5.3. Natural in vitro proteolysis of human milk derived LF: 
Because I was not able to produce any LF variant by molecular cloning, I had 
to focus on the alternative aside the cloning approach. Namely, the proteolytic 
generation of LF fragments to determine the Plg binding site of LF in 
subsequent biochemical assays. I subjected LF derived from human milk to in 
vitro proteolytic cleavage by pepsin and trypsin. According to literature, trypsin 
would yield the 2 iron- binding lobes, the N- and C-terminal halves of the 
molecule respectively, whereas pepsin is supposed to release the bioactive 
peptide LFcin. The two proteases were coupled to sepharose beads 
according to section 4.14. in order to separate them from digestion products 
after proteolysis. LF and enzyme coupled beads were incubated together at 
37°C at enzymes’ optimal pH while constantly shaking. Aliquots were taken at 
indicated time points and pH was readjusted with 1 M NaOH. The aliquots 
were used for SDS-PAGE and the gel was stained with Pierce® Silver Stain 
Kit in order to visualize all proteins and protein derived fragments. Pepsin 
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rapidly digested LF to smaller fragments, predominantly a 50 kDa fragment 
and a peptide smaller than 10 kDa. Latter might be the bioactive peptide 
LFcin that has the calculated molecular weight around 4-5 kDa. Trypsin 
digestion yielded 3 major fragments with molecular weights ranging from 30 to 
45 kDa, which could represent the iron-binding lobes. (see Fig. 5.3.) 
 
Figure 5.3. Natural in vitro proteolysis of human milk derived LF: 
LF (50 µg) derived from human milk (L0520 from Sigma) and enzyme coupled beads (100 µl) 
were incubated together in 0.035 M NaCl (1 ml total volume) adjusted to the enzymes optimal 
pH (for pepsin pH 2.5; for trypsin pH 8) and temperature (37°C) while constantly shaking. 
Aliquots were taken at indicated time points and pH was readjusted to 7 with 1 M NaOH. 
SDS-PAGE was run and the gel was silver-stained by Pierce® Silver Stain Kit.  
 
5.4. Binding assay with LF hydrolysates: 
In order to narrow down the binding region of LF to Plg, I used LF 
hydrolysates generated by pepsin (P) and trypsin (T) cleavage together with 
undigested LF (ctrl) in a binding assay. The idea was to confine the Plg 
binding region on LF by identifying corresponding LF fragments, which bound 
to Plg. To do so, I coated Plg, M6P/IGF2R or BSA (as a negative control) on 
wells of a 96-well plate at 37°C for 2 h. Then the wells were blocked 1 h at RT 
with 1% BSA, washed with PBS and afterwards incubated overnight on ice 
with hydrolysates. Next, unbound molecules were washed away with PBS and 
subsequently, bound molecules were released by addition of 10 µl 1x NR 
sample buffer. The individual samples were analyzed by means of SDS-
PAGE and Western blotting. Herewith, LF fragments bound to Plg or BSA 
respectively were to be visualized. The binding was performed under the low 
stringency (overnight binding, without detergent) conditions in order to obtain 
even weakly binding fragments; therefore the background binding of 
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undigested LF to the negative control (BSA) was strongly pronounced. I was 
able to identify one 50 kDa LF derived fragment of pepsin cleavage which was 
specifically binding to Plg and M6P/IGF2R. Yet, only little amounts could be 
detected, indicating that the 50 kDa fragment might not be the most 
determining part of LF in binding Plg. Moreover, no trypsin cleavage product 
was able to bind to Plg nor M6P/IGF2R and neither BSA. Consequently, it 
seems that upon cleavage of the full-length protein, the specific binding site 
either got lost or could not be detected by the polyclonal antibody used. (see 
Fig. 5.4.) 
 
 
 
Figure 5.4. Binding assay with LF hydrolysates 
The wells of a 96-well plate were coated for 2h at 37°C with 250 ng Plg (50 µl of 5 µg/ml Plg ), 
50 µl purified M6P/IGF2R (estimated concentration 5-10 µg/ml) or 1% BSA as a control. After 
blocking with 1% BSA and washing with PBS, the wells were incubated overnight on ice with 
pepsin and trypsin hydrolysates or undigested LF as a control. Bound LF fragments were 
detected by SDS-PAGE followed by Western blotting. Immunoblot (IB) was performed with a 
polyclonal biotinylated human anti-LF antibody. 
 
5.5. Design of LF derived peptides  
Since binding assays with pepsin and trypsin LF hydrolysates did not reveal 
specific binding fragments, the next option was to design synthetic LF derived 
peptides and use them to determine the binding sites in blocking assays. I 
designed four peptides, denoted pLF1, pLF2, pLF3 and pLF4. Again the main 
focus was directed on the C-terminal lysine of LF, therefore one of the 
peptides, pLF3, was made up of the C-terminal 19 amino acids of human LF 
encompassing the terminal lysine. Peptide pLF4 was designed to serve as a 
control, hence it comprised the same amino acids as pLF3, but randomly 
A novel interaction partner of plasminogen in regulation of fibrinolysis       Alexander Zwirzitz  
 38 
arranged. The peptide pLF2 was derived from the N-terminal part of LF near 
the helix linker region to emcompass the LFampin’s sequence and also 
featured a C-terminal lysine that might have got exposed upon trypsin 
cleavage of full-length LF. Finally, pLF1 was derived from LF’s N-terminal end 
and was designed to cover parts of LFcin. (see Fig. 5.5.) In particular, pLF1 
comprised the most relevant amino 
acids concerning LPS neutralizing 
activity (Zhang et al., 1999). When 
designing the peptides I attached 
great importance to the secondary 
structure to avoid any effects merely 
caused due to conformational 
differences. Therefore I subjected 
the peptide sequences to two 
independent structure prediction 
servers (see section 4.15.). Both 
servers yielded that all peptides 
share a common secondary 
structure, illustrated with indicated 
positions within the full-length LF in figure 5.5.: a coiled-coil region in the 
beginning and a helix motif followed by another short coiled-coil region. The 
peptides sequences are presented in Table 2 and highlighted in the protein 
sequence of LF in Appendix 8.2. 
 
5.6. Peptide mapping of antibodies: 
I first tested whether the synthetic LF derived peptides could be recognized by 
the available anti-human LF antibodies. Our polyclonal mouse anti-human LF 
antibody did not recognize any of the four LF-derived peptides I had designed. 
(see Figure 5.6.A) Then, I scanned four different monoclonal mouse anti-
human LF antibodies. By means of dot Western blot method I found that all 
monoclonal antibodies bound the full-length protein comparably well, except 
monoclonal antibody clone 3D5, which exerted only a moderate binding. 
Fig. 5.5. Peptide structures with indicated positions, 
modified from (Baker and Baker, 2009) – pLF1,2,3 
and the C-terminus are illustrated in blue. N and C 
termini are labelled with N and C respectively. N 
and C terminal lobes are subdivided in 2 domains 
each, denoted as N1, N2 and C1, C2. The helix 
linker region (H) is indicated in turquoise and iron 
ions are depicted in red. 
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However, none of the antibodies was able to detect any of the spotted LF-
derived peptides. (see Fig. 5.6.B) 
 
 
 
 
5.6. Peptide mapping of antibodies: 
LF and LF-derived peptides (1 µg each) were spotted onto PVDF membranes, which were 
washed, blocked and subsequently incubated with anti LF antibodies. In A, the membrane 
was incubated with the biotinylated polyclonal LF antibody ab25811. Bound primary antibody 
was detected by streptavidin-biotinylated horseradish peroxidase complex. In B, the 
membrane was incubated with different monoclonal antibodies (1D5, 4C5, 4E2, 3D5). Bound 
primary antibodies were detected by secondary rabbit anti-mouse IgG conjugated to 
horseradish peroxidase. 
 
5.7. Competition binding assay:  
Because pLFs could not be detected by antibodies and peptides in general 
display low coating efficiency on simple plastic plates, competition binding 
assays were the most convenient method to discover the definite binding site 
of LF. Hence, a binding assay in a cell-free system was performed in the 
absence or presence of indicated peptides. The underlying principle was that 
molecules containing the putative binding site would bind to coated Plg and 
therefore hinder the binding of LF to Plg. The competition of indicated 
peptides for LF binding to Plg was analyzed by means of a binding assay 
followed by SDS-PAGE and Western blotting. In these competition binding 
assays I increased the stringency (binding for 2h and use of 0.1% Triton X-
100) in order to see only specific effects (compare with Fig. 5.4.). Here I found 
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that pLF1, a synthetic peptide comprised of a 19 amino acid sequence stretch 
identical to human LFcin, interfered with the binding of full-length LF to coated 
Plg and therefore seems to be a compulsory region of the LF molecule when 
interacting with Plg. (see Fig. 5.7.1.)  
Figure 5.7.1. Representative WB analysis of competition binding assay - LF binding to 
Plg: 
The wells of a 96-well plate first were coated for 2 h at 37°C with 5 μg/ml Plg or 1% BSA 
(negative control) then blocked 1 h at RT with 1% BSA and incubated with or without 20 μg/ml 
of LF peptides (pLF1-4) or 5 mmol/L tranexamic acid (TA) for 2 h on ice. After 4-5x washing 
with 1x PBS, 20 μg/ml LF were added to each well and the binding in presence of assay 
molecules was analyzed by Western blotting. Immunoblot (IB) was done with mouse anti-
human LF 4E2 mAb. 
 
Densitometric quantification and statistical analysis of western blots revealed 
highly significant inhibition of the LF/Plg interaction in the presence of pLF1. 
Here, the binding to BSA was subtracted from Plg binding lanes and in 
addition a background correction for each individual lane was applied. 
Conversely, the lysine analogue tranexamic acid (TA) as well as the terminal 
lysine containing peptides pLF2 and pLF3 did not have a significant effect on 
the binding of LF to Plg. However, in case of co-administration of pLF3 the 
amount of LF bound to coated Plg probably was slightly yet not significantly 
(n.s.) reduced. (see Fig. 5.7.2.) 
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Figure 5.7.2. Densitometric WB quantification of competition binding assay - LF 
binding to Plg: 
The individual bars show the relative means with standard errors or the means of at least 
three independent experiments. The scrambled peptide pLF4 served as control and therefore 
was set as relative maximum of 100%. The immunoblots were quantified with the Fuji 
MultiGauge software as described in section 4.26. BSA lanes were subtracted from Plg lanes 
and in addition a background correction for each individual lane was applied.  
 
5.8. Inhibition of LF binding to Plg by pLF1 is concentration dependent: 
In order to get a better insight into the dynamics of the inhibitory action of 
pLF1, I conducted competition binding assays in the presence of different 
concentrations of LF peptide pLF1 and as a negative control the scrambled 
peptide pLF4. Herewith, I was able to show that the peptide pLF1 was a 
potent competitor for LF in binding Plg. Even pLF1’s concentrations as little as 
5 μg/ml considerably impaired the binding of LF to Plg. Upon addition of 40 
μg/ml of pLF1 the ability of LF to bind Plg was almost completely abolished 
(5.8.1.A), whereas in the control (pLF4) it was more or less unimpeded 
(5.8.1.B). 
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Figure 5.8.1. WB analysis of binding assay with different peptide concentrations:  
The wells of a 96-well plate were coated 2 h on 37°C with 5 μg/ml Plg or 1% BSA (negative 
control) then blocked 1 h with 1% BSA at RT and incubated 2 h on ice with increasing 
concentrations (0, 5, 10, 20 and 40 μg/ml) of either the LF resembling peptide pLF1 (Fig. 
5.8.1. A) or the scrambled peptide pLF4 (Fig. 5.8.1. B), which served as a control. After 4-5x 
washing with 1x PBS, LF (20 μg/ml) was added to each well and the binding in presence of 
peptides was analyzed by Western blotting. Immunoblot (IB) was done with the primary 
mouse anti-human LF 1C5 mAb.  
 
Quantification of at least three independent experiments is shown in Figure 
5.8.2. Statistical analysis revealed that merely 5 µg/ml of peptide pLF1 was 
sufficient to significantly reduce the binding of LF to Plg (p < 0.05). Upon 
addition of gradually increasing concentrations of pLF1 the binding was 
progressively debilitated (p < 0.01 for 10 µg/ml, p < 0.001 for 20 µg/ml and 40 
µg/ml) and reached a plateau at concentrations around 20-40 µg/ml. The 
calculated relative half maximum inhibitory concentration (relative IC50) of 
peptide pLF1, which was determined by a four-parameter logistic (4PL) 
B 
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nonlinear regression curve fit, is 6.038 µg/ml. The corresponding molar 
concentration is 2.8 µM.  
 
Figure 5.8.2. WB quantification of binding assay with different peptide concentrations:  
The individual bars show the relative means with standard errors or the means of at least 
three independent experiments. LF without any peptide was set at 100%. The immunoblots 
were quantified with the Fuji MultiGauge software. BSA lanes were subtracted from Plg lanes 
and in addition a background correction for each individual lane was applied. The relative 
IC50 value was determined by a 4PL nonlinear regression curve fit, in accordance with 
National Institutes of Health (NIH) assay guidance. (Assay Guidance Manual Version 5.0, 
2008, Eli Lilly and Company and NIH Chemical Genomics Center. Available online at: 
http://www.ncgc.nih.gov/guidance/manual_toc.html - last accessed 15.06.2011) Curve fitting 
was performed with MasterPlex ReaderFit, published by the MiraiBio Group of Hitachi 
Software Engineering America, Ltd. 
 
5.9. Dot far Western blot: 
In competition binding assays I was able to show that pLF1 interfered with the 
binding of LF to Plg. However, the exact molecule on which pLF1 was acting, 
namely LF or Plg, had not been determined with certainty. To examine if pLF1 
did bind to Plg or LF, dot far Western blots were performed as follows: LF and 
derived peptides (1 µg each) were spotted (directly pipetting 1 µl of a 1 mg/ml  
solution) onto a PVDF membrane, which then was blocked with 5% non-fat 
dry milk for 1 h and incubated with Plg (Fig. 5.9.A) or LF (Fig. 5.9.B) (each 1 
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µg/ml in TBST) for 1 h. Bound Plg or LF was detected by antibodies directed 
against Plg or LF, respectively. By means of dot far Western blotting I was 
able to confirm that Plg not only bound LF but in addition peptide pLF1 
(5.9.A), the very one competing with LF for the binding to Plg (see Fig.5.7.1. - 
5.7.2.). Furthermore, dot far Western blot revealed that LF was binding to 
pLF1 (5.9.B) as well.  
 
 
 
 
Figure 5.9. Dot far Western blot of LF and derived peptides 
LF and derived peptides (1 µg/ml each) were directly spotted on a PVDF membrane, which 
was afterwards blocked in 5 % non-fat dry milk and incubated with 1 µg/ml Plg (A) or LF (B) in 
TBST. The membrane was immunostained with mouse anti-human Plg (7Pg) in A and with 
biotinylated mouse anti-human-LF (LFb) in B.  
 
5.10. Cell surface activation of Plg in the presence of LF peptides: 
Next, I wanted to examine the impact of LF and derived peptides on the 
fibrinolytic system within a cellular environment. Therefore, Plg activation on 
the human epithelial kidney tumor cell line (TCL-598) was performed in the 
presence of LF, LF derived peptides (pLFs) or TA, the lysine analogue, which 
is known to effectively inhibit the conversion of Plg to Plm on the cell surface. 
Plg is supposed to bind to uPA, which is bound to its receptor uPAR on the 
surface of TCL cells, which were shown to express high amounts of both uPA 
B 
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and uPAR. (Koshelnick et al., 1997) Upon binding to uPAR, pro-uPA gets 
activated to uPA, which in turn triggers the conversion of Plg to active Plm 
(see Fig. 2). The chromogenic substrate S-2251 was used to monitor Plm 
activity. The substrate was hydrolyzed by active Plm and the cleavage 
product emitted light at a wavelength of 405 nm, which was measured every 
hour. In order to avoid non-specific Plm activity, the cells were seeded in 
serum-free medium and potentially free Plm was inhibited by addition of 
α2AP. Hence, only the effect of cell-surface activated Plm should have been 
perceived. Therefore, here one could directly read out cell-surface mediated 
Plg conversion to active Plm. The activation of Plg in the presence of LF was 
reduced to a level comparable to the anti-fibrinolytic drug TA, whereas none 
of the lactoferrin-derived peptides had a direct influence on Plg activation. 
(see Fig. 5.10.1)  
 
Figure 5.10.1 Surface activation of Plg in the presence of LF peptides: 
TCL cells (50.000/well) were seeded in serum-free RPMI 1640 medium in a 96-well plate 24 h 
before the assay. Plg (100 nM), the chromogenic Plm substrate S-2251 (1.6 nM) and α2AP (5 
µg/ml) were incubated together with assay molecules (20 µg/ml LF, pLFs or 10 nM TA ) in 
serum-free RPMI 1640 medium for 30 min on ice. Then the mixture was added to the cells 
and absorbance was measured every hour. The individual bars represent mean absorbance 
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levels, with standard deviations. Absorbance was generated by the Plm cleavage product of 
the chromogenic Plm substrate S-2251 (emits light at 405 nm). 
 
Since competition binding assays revealed that pLF1 obstructed the LF/Plg 
binding in a cell-free system, it might as well interfere with the LF induced 
inhibition of Plg activation in a cell system. Indeed, upon co-administration of 
pLF1 the decreased activation of Plg to Plm elicited by LF could be partly 
restored. (see Fig. 5.10.2.) 
 
 
Figure 5.10.2. Reconstitution of Plg surface activation  
TCL cells (50.000/well) were seeded in serum-free RPMI 1640 medium in a 96-well plate 24 h 
before the assay. Plg (100 nM) , the chromogenic Plm substrate S-2251 (1.6 nM) and α2AP 
(5 µg/ml) were incubated together with assayed molecules (20 µg/ml pLFs or 10 nM TA ) in 
serum-free RPMI 1640 medium for 30 min on ice. Then LF (20 µg/ml) was added to all wells 
except the control (-). The mixture was added to the cells and absorbance was measured 
every hour. The individual bars represent mean absorbance levels, with standard deviations. 
Absorbance was generated by the Plm cleavage product of the chromogenic Plm substrate S-
2251 (emits light at 405 nm). 
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5.11. Determination of natural LF – Plg interaction by blue native 
polyacrylamide gel electrophoresis: 
In order to study whether LF and Plg were actually interacting under 
physiological conditions, I examined human serum samples with blue native 
polyacrylamide gel electrophoresis (BN-PAGE). BN-PAGE is a method to 
isolate native protein complexes, maintaining their physiological context. 
Hence, BN-PAGE allows analysis of intact and functional native protein-
protein interactions. Protein complexes are dissected in the 1st dimension by 
blue native run and individual proteins are separated from their physiological 
complexes in the 2nd dimension by SDS-PAGE gel run. Analysis of human 
serum by this method revealed partial colocalization of LF and Plg in the high 
(left) and moderately high (middle) molecular complexes around 880 kDa and 
440 kDa, respectively. This human serum sample from a patient with liver 
disorder was used in former studies of our group (approved by the Ethical 
Committee of the Medical University of Vienna). Therein, it was reported that 
soluble M6P/IGF2R and Plg appeared in human serum within a high (above 
880 kDa) and a moderately high (around 440 kDa) molecular complex, similar 
to those described here. (Leksa et al., 2011) Consequently, LF, Plg and 
soluble M6P/IGF2R might be part of the same physiological protein 
complexes. The lower (right) molecular weight bands, which are smaller than 
272 kDa, might represent individual molecules and/or homo-oligomers. 
Actually, these low molecular weight bands could probably mirror interacting 
LF and Plg molecules. (see Fig. 5.11.) 
 
 
 
Figure 5.11. Blue native polyacrylamide gel electrophoresis: 
Serum samples were loaded on a BN-PAGE gel. The gel was run at 4°C at 80 V for 4 h. Then 
voltage was increased to 120 V o/n. The next day the cathode buffer was exchanged to 
slightly blue cathode buffer and the gel was run 2 h. The gel was cut into individual sample 
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stripes, which were used for the 2nd dimension (SDS-PAGE). Afterwards the gel was blotted 
followed by staining with either the mouse anti-human Plg mAb 7Pg or biotinylated mouse 
anti-human LFb antibody. Ferritin and jack bean urease were used as markers.  
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6. Discussion:  
 
In preliminary studies LF was detected as interaction partner of M6P/IGF2R, 
which in turn formerly was identified to bind Plg. Furthermore, also LF and Plg 
demonstrated direct binding in preliminary experiments. Many of its known 
interactions can be attributed to Plg’s affinity for binding C-terminal lysines. 
Since LF’s amino acid sequence displays a C-terminal lysine, I put high 
priority on manipulation of LF’s C-terminus.  
I considered two initial approaches: first, the generation of LF C-terminal 
mutants and truncations by molecular cloning, and second, the enzymatic 
fragmentation of LF. Concerning the generation of recombinant LF variants, I 
cloned several LF-derived mutants into subcloning vectors (pGEM-T easy and 
pBluescript KS-), but I was unable to produce any mammalian expression 
vector (pBMN) containing either the full-length protein, the C-terminal lysine to 
threonine mutant or any truncated form of LF. My hypothesis on this issue is 
that retroviral promoters which are generally used in mammalian expression 
vector systems are somewhat leaky in bacteria (Kashanchi and Wood, 1989; 
Lewin et al., 2005), thereby resulting in protein expression which in this 
particular case might lead to bacteriostatic action of LF and its mutant forms. 
By supplementing agar plates with iron, I intended to compensate in particular 
LF’s iron sequestrating effect. Although bacteria in general were able to 
survive these high-iron conditions, I could not detect any clone transformed 
with LF variants. However, the depletion of iron is not the only bactericidal 
mechanism of LF. One of the truncated forms of LF represents ΔLF and 
therefore lacks the potent anti-microbial domain LFcin. Nevertheless, even 
bacteria transformed with ΔLF constructs did not grow. Consequently, LF and 
its truncated forms might be able to act in an antimicrobial way through a 
combination of the iron sequestration, the action of the very potent N-terminus 
(LFcin), LFampin’s action and maybe another unknown mechanism. Other 
research groups might have experienced similar difficulties in cloning human 
LF, since they circumvented this issue by introducing an intron which could be 
spliced in eukaryotic cells only. When this construct is expressed in bacterial 
cells, the intron disrupts LF’s inherent antimicrobial activity, thereby allowing 
A novel interaction partner of plasminogen in regulation of fibrinolysis       Alexander Zwirzitz  
 50 
survival of bacteria. As soon as the expression vector containing LF is 
transferred into mammalian cells, the intron is spliced out and a fully 
functional LF is expressed. (Bissonnette et al., 2006) However, we have 
decided to apply different strategies.  
The first alternative step was to imitate natural proteolytic digest of LF as it 
would occur within the human digestive system and identify LF fragments that 
probably bind Plg. When proteolytically digested with pepsin, LF is rapidly 
degraded to smaller fragments. (see fig. 5.3.) In addition to a 50 kDa fragment 
also a peptide smaller than 10 kDa can be detected, which may be LFcin (4-5 
kDa). In case of trypsin digest, three major fragments with molecular weights 
of approximately 30-35, 35-40 and 45 kDa were generated. These results are 
diverging from literature where the trypsin digest is supposed to yield two iron 
binding lobes (Brock et al., 1976). However, two of the three fragments 
observed by us still may represent the two lobes and the third one might 
represent an incompletely cleaved fragment. Additionally, LF cleavage might 
be different in dependence on its iron-status or other general digestion 
affecting parameters like pH for instance.  
In vitro binding assays with the pepsin and trypsin LF hydrolysates revealed 
that the approximately 50 kDa fragment, generated by pepsin cleavage, 
bound to Plg and M6P/IGF2R. (see fig. 5.4.) We further see in figure 5.4. that 
LF appears on SDS-PAGE gels as a double band that probably depends on 
its glycosylation status (Spik et al., 1994). The very low staining of this 50 kDa 
fragment is propably due to the fact that upon digestion of the full-length 
molecule the most decisive and specific binding region is either destroyed or 
not recognized by our antibodies.  
Because cloning as well as in vitro proteolysis concepts did not provide LF 
fragments which permit mapping of the definite Plg binding region, the next 
approach was to design synthetic peptides derived from LF, and use them in 
subsequent biochemical experiments to characterize the Plg interaction site. 
Via in vitro binding assays I was able to demonstrate not only that LF bound 
to Plg, but in addition that a small synthetic peptide derived from the bioactive 
LF peptide LFcin could obstruct the aforementioned interaction. Figure 5.7.1. 
illustrates that the LFcin-like peptide pLF1 hampers binding of LF to Plg. In 
contrast to the scrambled peptide pLF4 or C-terminal lysine containing 
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peptides pLF2 and pLF3, the amount of LF bound to Plg is significantly 
reduced (fig. 5.7.2.) in the presence of peptide pLF1 when compared with the 
control (LF without additional molecules). Moreover, TA which is a lysine 
derivative commonly used as a potent anti-fibrinolytic drug does not affect the 
binding of LF to Plg, which provides a strong evidence that Plg’s affinity for C-
terminal lysines in case of LF is not responsible for the establishment of this 
specific interaction. The four peptides have been synthesized so that they 
mimic defined parts of LF (see Table 2). Moreover, the peptides were 
designed in such a way that they all resemble each other as well as their 
originating location within full-length LF in terms of secondary structure (see 
Fig. 5.5.). Thus, potential effects provoked by structural peculiarities can be 
largely excluded. The structure of the peptides was determined by structure 
prediction algorithms as described in 4.15. However, these algorithms are not 
able to compute whether the peptides are circular. Since naturally occurring 
LFcin is described to be circular (Bellamy et al., 1992b), the physiological 
relevance of pLF1 has to be verified. In theory, pLF1 might form an 
intramolecular bond based on its two cysteine residues, although these two 
cysteines are not interacting in the natural LFcin. Instead, they are elements 
of two discrete cysteine bonds formed between two additional cysteines which 
occur in LFcin (Hunter et al., 2005) but not in the shorter synthetic peptide 
pLF1. Hence, pLF1 might be linear due to steric hindrance entailed by the 
close proximity of the two cysteines. Anyway, the circumstance that pLF1 
might not be comparable to natural LFcin has to be taken into account before 
transforming results shown here to physiological situations.  
To study the effectiveness of the inhibitory peptide pLF1, binding assays were 
repeated with increasing concentrations of pLF1 and the control peptide pLF4. 
Herein I was able to show that upon addition of increasing concentrations of 
pLF1 the binding of LF to Plg was progressively decreased, (see Fig. 5.8.1.A) 
whereas the scrambled control peptide pLF4 did not affect the binding. (see 
Fig. 5.8.1.B) The calculated relative half inhibitory concentration (IC50) is 
6.038 µg/ml, demonstrating that even molar concentrations as low as 2.8 µM 
of pLF1 (M = 2162.48 g/mol) are sufficient to significantly inhibit interaction of 
LF and Plg. (see Fig. 5.8.2.) A very weak background binding to BSA (control) 
was observed, which I subtracted. A slight decrease in BSA binding can be 
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observed in case of pLF1. On account of this fact one might argue that pLF1 
is not only specifically weakening the binding of LF to Plg but also to BSA or 
probably proteins in general. Indeed, the lower the stringency is the more LF 
tends to bind to BSA (see figure 5.4.). If the stringency is increased, as it was 
the case in competition binding assays, BSA binding is generally reduced 
(see figure 5.7.). To further limit the influence of dissimilar background BSA 
binding, I subtracted band density values of BSA binding from Plg binding, 
thereby generating a net Plg binding value.  
Yet, the question whether pLF1 is specifically interacting with Plg cannot be 
answered by competition binding assays in this vein. The inhibitory peptide 
pLF1 might inhibit the LF/Plg interaction by binding to Plg as well as by 
binding to LF. Even though the assay molecules, among pLF1, were pre-
incubated for half an hour on ice with coated Plg on the plate, one could not 
entirely exclude that they still bind to LF. Thus, I performed a dot far Western 
blot, to provide evidence for the direct interaction of the inhibitory peptide 
pLF1 and Plg. Dot far Western blot is derived from a method called far 
Western blot, wherein prey proteins transferred onto a membrane are 
incubated with another protein, the bait, which is either tagged itself or 
detected by a primary antibody directed against it. Hereby, I proved that Plg 
was directly binding to LF and to the inhibitory peptide pLF1. In addition, Plg 
binds to a minor extent to pLF3 in dot far Western blots (see fig. 5.9.1.A), 
which nicely mirrors plate binding assays: In plate binding assays pLF3 was 
also minimally reducing the binding. (see fig. 5.7.1. & 5.7.2.) Furthermore, dot 
far Western blots disclose that LF is directly binding to pLF1 (see fig. 5.9.1.B). 
Accordingly, pLF1 might interfere with the LF/Plg interaction on both 
molecules.  
The fact that the Plg binding peptide pLF1 is not detectable by antibodies (see 
figure 5.6.) might explain why I was not able to recognize any specific Plg 
binding fragment in binding assays with LF hydrolysates (see figure 5.4.). 
Since pLF1 covers parts of LFcin, which according to literature is produced 
upon proteolytic processing of LF by pepsin, LFcin is supposed to bind Plg 
too. However, it might as well not be recognized by antibodies, therefore it 
could not be seen in binding assays with pepsin hydrolysates. 
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To investigate the effect of LF or LF derived peptides on the fibrinolytic 
system at the cellular level, Plg activation was studied in a cellular model. A 
chromogenic Plm substrate allows studying the conversion of Plg to active 
Plm. In addition, working with serum-free media and blocking potentially free 
Plm with α2AP, a serine protease inhibitor, ensures measurement of the cell 
surface-bound Plg conversion only. TCL-598 cells were used because they 
are known to express sufficient levels of both the Plg activating enzyme uPA 
and its receptor uPAR. (Koshelnick et al., 1997) I demonstrate that LF is 
effectively restraining the conversion of Plg to Plm. Actually, LF is comparably 
potent to the widely used anti-fibrinolytic drug TA (see fig. 5.10.1.), whereas 
none of the peptides directly altered the activation of Plg. However, upon co-
administration of LF and the individual peptides, the LFcin-like peptide pLF1 
tended to compensate for the impairment of Plg activation by LF (see fig. 
5.10.2.), which suggests that by binding of pLF1 to Plg alone the Plg 
activation is not affected. Instead, pLF1 seems to obstruct the binding of LF to 
Plg, thereby restricting the inhibition of Plg activation by LF described above. 
Obviously, the full-length LF protein is able to limit the conversion of Plg to 
Plm, whereas pLF1 does not interfere with its activation, although it is binding 
to Plg. Since pLF1 is a small synthetic peptide comprised of only 19 amino 
acids, it might be simply too small to deter Plg activation, consequently 
suggesting that it needs the whole LF molecule to either mask a binding site 
of Plg for its converting enzyme uPA or sterically inhibit the proteolytic 
processing of Plg to active Plm. In turn, by blocking the binding site of LF on 
Plg, pLF1 seems to be able to confine LF’s Plg activation diminishing action, 
thereby promoting fibrinolytic function and probably providing a basis for 
treatment of diseases with underlying fibrinolytic dysfunctions.  
It would be highly interesting if Plm can cleave LF, thereby yielding a natural 
LFcin-like peptide, which acts comparably to pLF1. If this were the case, Plm 
would feature the ability of generating a feedback loop to protect its activation 
from inhibition by LF. As described (Aslam and Hurley, 1997; Dalsgaard et al., 
2008), Plm is indeed able to cleave LF but these authors could not identify 
any peptide generated by the Plm cleavage akin to LFcin. Furthermore, it 
would be interesting if the naturally occurring LFcin produced by pepsin 
cleavage behaves analogously to the synthetic peptide pLF1. Undoubtedly, if 
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these scenarios were true they would in principle question the physiological 
relevance of the inhibition of Plg activation by LF, because the counteracting 
peptide LFcin might always be present under physiological circumstances. 
However, BN-PAGE analysis suggests the interaction in some way. Since 
BN-PAGE conserves physiological protein complexes, which can be further 
separated by a 2nd dimension SDS-PAGE, it is possible to shed light on 
natural protein-protein interactions with this method. Analysis of human serum 
by BN-PAGE demonstrated that LF and Plg might occur within the same 
molecular protein complexes in circulation. This provides a hint for possible 
physiological interaction of LF and Plg.  
Adequate Plm activity seems to be an integral factor for accurate regulation of  
immune function. By degradation of the extracellular matrix it enables the 
migration of immune cells, e.g. neutrophils (Herren et al., 2001). LF might 
decrease the motility of immune cells by limiting Plg activation resulting in 
reduced ECM degradation. Consequently, LF may not only act synergistically 
to immune responses, e.g. via mediating T and B cell maturation (Zimecki et 
al., 1991; Zimecki et al., 1995), but in addition as an indirect 
immunosuppressant to avoid the overshooting immune reactions. As already 
mentioned, certain bacteria use the Plg system to invade tissues. In these 
cases, LF might be able to limit bacterial invasion by inhibiting Plg activation. 
Increasing evidences evolved during the last decade for Plm playing a crucial 
role in development and progression of Alzheimers disease. For instance, it 
was shown that brain Plm enhanced the cleavage of APP and degrades Aβ. 
Furthermore, Plm activity is reduced in Alzheimer dementia patients’ brains, 
hence endorsing its role in Alzheimers disease (Ledesma et al., 2000; Tucker 
et al., 2000). Besides, LF was shown to accumulate in Alzheimers disease 
patients’ brains (Kawamata et al., 1993). Moreover, Alzheimer dementia 
mouse models provide indications of LF being involved in the disease by 
detecting LF depositions in brains of Alzheimers disease mouse models. 
(Wang et al., 2010) These records suggest a possible interplay of Plg and LF 
in this disease. Due to the accumulation of LF, Plg activation might be 
decreased, consequently promoting the formation of senile plaques by 
reduced Aβ cleavage. Since the synthetic peptide pLF1 is shown here to be a 
potent blocker of the LF/Plg inhibitory interaction, pLF1 represents a new 
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promising candidate for therapeutic approaches in treatment of Alzheimers 
disease. Probably even the naturally occurring LFcin or other LFcin-derived 
peptides might be used as therapeutics in treatment of Alzheimers disease. 
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8. Appendices: 
 
8.1. Appendix 1 - DNA Sequence of human LF (NCBI reference sequence: 
NM_002343.3): The primers described in 4.5. are depicted. 
 
AGAACCAGGACAGGTGAGGTGCAGGCTGGCTTTCCTCTCGCAGCGCGGTG 50 
TGGAGTCCTGTCCTGCCTCAGGGCTTTTCGGAGCCTGGATCCTCAAGGAA 100 
CAAGTAGACCTGGCCGCGGGGAGTGGGGAGGGAAGGGGTGTCTATTGGGC 150 
AACAGGGCGGGGCAAAGCCCTGAATAAAGGGGCGCAGGGCAGGCGCAAGT 200 
GGCAGAGCCTTCGTTTGCCAAGTCGCCTCCAGACCGCAGACATGAAACTT 250 
GTCTTCCTCGTCCTGCTGTTCCTCGGGGCCCTCGGACTGTGTCTGGCTGG 300 
CCGTAGGAGGAGTGTTCAGTGGTGCGCCGTATCCCAACCCGAGGCCACAA 350 
AATGCTTCCAATGGCAAAGGAATATGAGAAAAGTGCGTGGCCCTCCTGTC 400 
AGCTGCATAAAGAGAGACTCCCCCATCCAGTGTATCCAGGCCATTGCGGA 450 
AAACAGGGCCGATGCTGTGACCCTTGATGGTGGTTTCATATACGAGGCAG 500 
GCCTGGCCCCCTACAAACTGCGACCTGTAGCGGCGGAAGTCTACGGGACC 550 
GAAAGACAGCCACGAACTCACTATTATGCCGTGGCTGTGGTGAAGAAGGG 600 
CGGCAGCTTTCAGCTGAACGAACTGCAAGGTCTGAAGTCCTGCCACACAG 650 
GCCTTCGCAGGACCGCTGGATGGAATGTCCCTATAGGGACACTTCGTCCA 700 
TTCTTGAATTGGACGGGTCCACCTGAGCCCATTGAGGCAGCTGTGGCCAG 750 
GTTCTTCTCAGCCAGCTGTGTTCCCGGTGCAGATAAAGGACAGTTCCCCA 800 
ACCTGTGTCGCCTGTGTGCGGGGACAGGGGAAAACAAATGTGCCTTCTCC 850 
TCCCAGGAACCGTACTTCAGCTACTCTGGTGCCTTCAAGTGTCTGAGAGA 900 
CGGGGCTGGAGACGTGGCTTTTATCAGAGAGAGCACAGTGTTTGAGGACC 950 
TGTCAGACGAGGCTGAAAGGGACGAGTATGAGTTACTCTGCCCAGACAAC 1000 
ACTCGGAAGCCAGTGGACAAGTTCAAAGACTGCCATCTGGCCCGGGTCCC 1050 
TTCTCATGCCGTTGTGGCACGAAGTGTGAATGGCAAGGAGGATGCCATCT 1100 
GGAATCTTCTCCGCCAGGCACAGGAAAAGTTTGGAAAGGACAAGTCACCG 1150 
AAATTCCAGCTCTTTGGCTCCCCTAGTGGGCAGAAAGATCTGCTGTTCAA 1200 
GGACTCTGCCATTGGGTTTTCGAGGGTGCCCCCGAGGATAGATTCTGGGC 1250 
TGTACCTTGGCTCCGGCTACTTCACTGCCATCCAGAACTTGAGGAAAAGT 1300 
GAGGAGGAAGTGGCTGCCCGGCGTGCGCGGGTCGTGTGGTGTGCGGTGGG 1350 
CGAGCAGGAGCTGCGCAAGTGTAACCAGTGGAGTGGCTTGAGCGAAGGCA 1400 
GCGTGACCTGCTCCTCGGCCTCCACCACAGAGGACTGCATCGCCCTGGTG 1450 
CTGAAAGGAGAAGCTGATGCCATGAGTTTGGATGGAGGATATGTGTACAC 1500 
TGCAGGCAAATGTGGTTTGGTGCCTGTCCTGGCAGAGAACTACAAATCCC 1550 
AACAAAGCAGTGACCCTGATCCTAACTGTGTGGATAGACCTGTGGAAGGA 1600 
TATCTTGCTGTGGCGGTGGTTAGGAGATCAGACACTAGCCTTACCTGGAA 1650 
CTCTGTGAAAGGCAAGAAGTCCTGCCACACCGCCGTGGACAGGACTGCAG 1700 
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GCTGGAATATCCCCATGGGCCTGCTCTTCAACCAGACGGGCTCCTGCAAA 1750 
TTTGATGAATATTTCAGTCAAAGCTGTGCCCCTGGGTCTGACCCGAGATC 1800 
TAATCTCTGTGCTCTGTGTATTGGCGACGAGCAGGGTGAGAATAAGTGCG 1850 
TGCCCAACAGCAACGAGAGATACTACGGCTACACTGGGGCTTTCCGGTGC 1900 
CTGGCTGAGAATGCTGGAGACGTTGCATTTGTGAAAGATGTCACTGTCTT 1950 
GCAGAACACTGATGGAAATAACAATGAGGCATGGGCTAAGGATTTGAAGC 2000 
TGGCAGACTTTGCGCTGCTGTGCCTCGATGGCAAACGGAAGCCTGTGACT 2050 
GAGGCTAGAAGCTGCCATCTTGCCATGGCCCCGAATCATGCCGTGGTGTC 2100 
TCGGATGGATAAGGTGGAACGCCTGAAACAGGTGTTGCTCCACCAACAGG 2150 
CTAAATTTGGGAGAAATGGATCTGACTGCCCGGACAAGTTTTGCTTATTC 2200 
CAGTCTGAAACCAAAAACCTTCTGTTCAATGACAACACTGAGTGTCTGGC 2250 
CAGACTCCATGGCAAAACAACATATGAAAAATATTTGGGACCACAGTATG 2300 
TCGCAGGCATTACTAATCTGAAAAAGTGCTCAACCTCCCCCCTCCTGGAA 2350 
GCCTGTGAATTCCTCAGGAAGTAAAACCGAAGAAGATGGCCCAGCTCCCC 2400 
AAGAAAGCCTCAGCCATTCACTGCCCCCAGCTCTTCTCCCCAGGTGTGTT 2450 
GGGGCCTTGGCCTCCCCTGCTGAAGGTGGGGATTGCCCATCCATCTGCTT 2500 
ACAATTCCCTGCTGTCGTCTTAGCAAGAAGTAAAATGAGAAATTTTGTTG 2550 
ATATTCTCTCCTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2593 
 
8.2. Appendix 2 - Protein sequence of human LF (NCBI reference sequence 
ID: NP_002334.2): The peptides described in 4.15. are depicted. 
 
MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEATKCFQWQRNMRKVRG 50 
PPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEV 100 
YGTERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGT 150 
LRPFLNWTGPPEPIEAAVARFFSASCVPGADKGQFPNLCRLCAGTGENKC 200 
AFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLC 250 
PDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKD 300 
KSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNL 350 
RKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCI 400 
ALVLKGEADAMSLDGGYVYTAGKCGLVPVLAENYKSQQSSDPDPNCVDRP 450 
VEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTG 500 
SCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCVPNSNERYYGYTGA 550 
FRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRK 600 
PVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKF 650 
CLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSP 700 
LLEACEFLRK 710 
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8.3. Appendix 3 - Cloning vector maps: 
 
  
 
Taken from OrbiGen product datasheet 
Taken from Promega product datasheet 
A novel interaction partner of plasminogen in regulation of fibrinolysis       Alexander Zwirzitz  
 59 
Table 1 - Primer sequences: 
Fw1:   5’ – GTAATACGACTCACTAAAGCTTGGCCGCG – 3’ in vector 
Fw2:  5’ – AGAAGCTTCGTTTGCCAAGTCGCCTCCAG – 3’ in 5’ UTR 
Fw3: 5’ – GTAAGCTTATGAGAAAAGTGCGTGGCCCT - 3’ at ~400 bp 
Rev1:  5’ – TTGCGGCCGCTTACTTCCTGAGGAATTC – 3’ full-length 
Rev2: 5’ – TTGCGGCCGCTTACGTCCTGAGGAATTC – 3’ C-term. K-T 
Rev3: 5’ – GCGCGGCCGCGCCTCAGTCACAGGCTTCC – 3’ at ~2000 bp 
Rev4:  5’ – AGGCGGCCGCAGTCCTCTGTGGTGGAGGC – 3’ at ~1400 bp 
Rev5:  5’ – CTGCGGCCGCGCAGCTGACAGGAGGGC – 3’ at ~400 bp 
 
Table 2 - Peptide sequences: 
name location sequence length 
pLF1 N-terminal GRRRSVQWCAVSQPEATKC 19 amino acids 
pLF2 middle EDAIWNLLRQAQEKFGKDK 19 amino acids 
pLF3 C-terminal NLKKCSTSPLLEACEFLRK 19 amino acids 
pLF4 scrambled NFRTKSCPLELAKELKLCS 19 amino acids 
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9. List of symbols, acronyms and abbreviations: 
 
ΔLF delta lactoferrin 
µ micro 
4PL four parameter logistic 
Aβ amyloid beta 
amp  ampicillin 
APP amyloid precursor protein 
APS ammonium persulfate 
BN-PAGE blue native polyacrylamid gel electrophoresis 
BSA bovine serum albumin fraction V 
CB coupling buffer 
CNBr cyanogen bromide 
DMSO dimethylsufloxide 
EDTA ethylenediaminetetraacetic acid 
EtBr ethidiumbromide 
EtOH ethanol 
FCS fetal calf serum 
g gram 
h hour 
hLF human lactoferrin 
HRP horseradish peroxidase 
IB immunoblot 
IC50 half maximum inhibitory concentration 
IPTG Isopropyl-β-D-thiogalactopyranosid 
kDa kilo Dalton 
L liter 
LB lysogeny broth 
LF lactoferrin 
LFampin lactoferrampin 
LFcin lactoferricin 
m milli 
M molar 
M6P mannose 6-phosphate 
M6P/IGF2R mannose 6-phosphate/insulin-like growth factor 2 receptor 
mAb monoclonal antibody 
MeOH methanol 
min or ‘ minute 
n nano 
o/n overnight 
PAI Plasminogen activator inhibitor 
PBS phosphate buffered saline 
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pLF lactoferrin derived peptide 
Plg plasminogen 
PVDF polyvinylidenfluoride 
RT room temperature 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec. or ‘’ second 
TAE tris-acetate-EDTA buffer 
TBS  tris buffered saline 
TBST tris buffered saline + 0.1% Tween 20® 
TEMED  tetramethylethylenediamine 
tPA tissue plasminogen activator 
u unit 
uPA urokinase-type plasminogen activator 
uPAR  urokinase-type plasminogen activator receptor 
w/o without 
WB western blot 
X-Gal bromo-chloro-indolyl-galactopyranoside 
vWF van Willebrand factor 
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11. Zusammenfassung:  
 
Die Fibrinolyse stellt einen lebenswichtigen Mechanismus zur 
Aufrechterhaltung des hämostatischen Gleichgewichtes dar. Durch die 
Auflösung von Blutgerinnseln (Thromben) mit Hilfe des Enzyms Plasmin wirkt 
es der Koagulation entgegen. Plasmin baut Fibrinpolymere ab welche den 
Hauptbestandteil von Thromben  darstellen. Dabei stellt die Aktivierung von 
inaktivem Plasminogen zu aktivem Plasmin einen wesentlichen Schritt dieses 
durch eine Vielzahl an Enzymen regulierten Prozesses dar. Zusätzlich  
ermöglicht Plasmin die Migration von z.B. Immun- und Endothelzellen. 
Aufgrund seines breiten Wirkungsspektrums spielt Plasmin samt seinen 
regulierenden Molekülen nicht nur in physiologischen, sondern auch in 
pathologischen Prozessen eine wichtige Rolle. Im Fall von Morbus Alzheimer 
sind sowohl der Gehalt an Plasminogen als auch die Aktivität von Plasmin im 
Gehirn vermindert. Weil Plasmin das Peptid Amyloid-beta abbaut, welches die 
für Alzheimer Dementia charakteristischen senilen Plaques bildet, könnte es 
eine zentrale Rolle in der Entstehung oder im Verlauf dieser Krankheit 
spielen. Andererseits ermöglicht Plasmin die Metastasierung von Krebszellen 
durch den Abbau von Komponenten der extrazellulären Matrix. So können 
Tumorzellen dem Immunsystem oder lokalen Nähstoff-Beschränkungen 
entkommen. In der vorliegenden Arbeit wird ein neuer Regulator des  
fibrinolytischen  Systems charakterisiert. Die Bindung an Plasminogen und die 
daraus resultierenden Konsequenzen werden mithilfe von 
molekularbiologischen, biochemischen und zellbiologischen Methoden 
untersucht. Schließlich wird ein synthetisches, von diesem regulatorischen 
Protein abgeleitetes Peptid vorgestellt, welches einen therapeutischen Ansatz 
darstellen könnte. 
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